Quantcast

Latest Sequenom Inc. Stories

2014-07-29 16:27:48

62% Revenue Growth as Reimbursement and Testing Volumes Improve SAN DIEGO, July 29, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $39.8 million for the second quarter of 2014, an increase of 62% compared to revenues of $24.5 million for the second quarter of 2013. The Bioscience business segment, which was sold on May 30, 2014, has been accounted for as a discontinued...

2014-07-29 16:27:45

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company that provides innovative genetic analysis solutions, and Mayo Medical Laboratories (MML), the third-largest provider of esoteric laboratory services in the United States, have announced a license agreement for noninvasive prenatal testing patents and applications. "We have great appreciation for Mayo Clinic's commitment to research, innovation, and patient care, and we welcome the...

2014-07-22 08:30:52

SAN DIEGO, July 22, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced its wholly owned subsidiary, Sequenom Laboratories, will soon begin reporting on the presence of three additional clinically relevant subchromosomal microdeletions as part of the Enhanced Sequencing Series (ESS) for its MaterniT21(TM) PLUS laboratory-developed test. The microdeletions added include 11q deletion (Jacobsen...

2014-07-15 08:27:35

SAN DIEGO, July 15, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the second quarter of 2014 after closing of the NASDAQ Global Market on Tuesday, July 29, 2014. A conference call hosted by William Welch, Chief Executive Officer, and other members of senior management will take place on the same day at 5:00 p.m. EDT (2:00 p.m. PDT) and will be webcast...

2014-06-19 08:28:14

SOPHIA ANTIPOLIS, France, and SAN DIEGO, June 19, 2014 /PRNewswire/ -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(TM) portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes...

2014-06-19 08:25:52

LONDON, June 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Prenatal Testing Market in the US 2014-2018 http://www.reportbuyer.com/pharma_healthcare/diagnostics/prenatal_testing_market_us_2014_2018.html TechNavio's analysts forecast the Prenatal Testing market in the US to grow at a CAGR of 5.43 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of fetal health-related...

2014-06-16 08:28:27

SAN DIEGO, June 16, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, announced today that it has received premarket 510(k) clearance from the United States Food and Drug Administration (FDA) to market its IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx(TM) System. The IMPACT Dx Factor V Leiden and Factor II Genotyping Test is performed on the IMPACT Dx System, and is indicated...

2014-06-16 08:28:21

MADISON, N.J. and SAN DIEGO, June 16, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced an agreement under which Quest will offer national access to Sequenom Laboratories' MaterniT21(TM) PLUS laboratory-developed test (LDT). Using a maternal blood sample, the noninvasive prenatal test (NIPT)...

2014-06-16 04:21:39

IMPACT Dx(TM) Combined Function System Will Also Be Available in the European Union SAN DIEGO, June 16, 2014 /PRNewswire/ -- Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., was notified today by Sequenom, Inc. that it received premarket clearance from the U.S. Food and Drug Administration (FDA) for the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx(TM) System. The IMPACT Dx(TM) Factor V Leiden and Factor II...

2014-06-09 08:28:07

SAN DIEGO, June 9, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, announced today its wholly owned subsidiary, Sequenom Laboratories, has signed a national agreement with a leading health insurance company covering 13 million people throughout the United States, to provide the MaterniT21(TM) PLUS laboratory-developed test (LDT). The addition of this contract brings the number of covered lives...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related